Ad Astra Diagnostics Receives Funding for Groundbreaking Technology
System targets faster, earlier, easier CBC results and severe infection detection
Ad Astra Diagnostics (AAD), a champion of rapid diagnostic and data systems, has exciting news to share regarding its latest advancements in healthcare technology. The company has been awarded a significant federal contract worth $5 million, with the prospect of additional funding up to $12.6 million. This funding will facilitate the development of a cutting-edge diagnostic system, specifically aimed at providing faster complete blood count (CBC) test results and enhancing the detection of severe infections, prominently including sepsis.
Innovative Design and Purpose of the QScout™ CBC System
AAD's innovative QScout™ CBC diagnostic system is designed not just for efficiency but also for practicality. It promises to be the most comprehensive patient-side CBC available, paving the way as the first to report immature granulocytes and neutrophil-to-lymphocyte ratios in various community settings such as doctor's offices, cancer treatment centers, and even ambulances. This feature aims for earlier and more accurate identification of severe infections.
Joy Parr Drach, CEO of AAD, stated, "The coupling of a full CBC with a sepsis risk score on a portable and accessible platform will broaden the market and increase vital access to crucial on-site testing. This development is aimed at improving the early identification of severe illness, which is pivotal in preventing unnecessary fatalities due to infections." Drach continued on emphasizing that timely diagnosis is critical in protecting patients suffering from infections. Current tools for early diagnosis before hospitalization are limited, making this advancement particularly valuable.
Building on Previous Success: The QScout RLD
The QScout CBC system builds upon the previously successful QScout RLD, which attained FDA 510(k) clearance after undergoing rigorous field trials that demonstrated comparable accuracy to central laboratory tests. Also noteworthy is that the QScout inventions hold an impressive 11 patents to its name. Further, the QScout RLD's development received support from BARDA, a unit within the U.S. Department of Health and Human Services focused on preparedness and response initiatives.
This innovation is poised to include several enhancements such as a smaller footprint and improved diagnostic features. The system is ingeniously designed as a “lab in a box,” equipped with a computer, high-quality microscope, advanced camera, and robotics. To conduct a test, users simply place a blood sample, whether from a finger prick or venous draw, onto a cost-effective cartridge and insert it into the QScout Lab. No complicated sample preparation is required, allowing results to be processed via artificial intelligence algorithms that swiftly identify cells and their parameters, delivering results within approximately two minutes.
Real-World Applications and Support
This new initiative has gained backing from federal sources, primarily the Department of Health and Human Services and the Biomedical Advanced Research and Development Authority, affirming its importance in advancing healthcare technology. Jon Baker, Director of Laboratories at the University of Michigan Health – Sparrow, shared, "We are thrilled to witness this vital tool being funded. It aims to facilitate efficiency in emergency departments, ensuring rapid care for those who need it while keeping unnecessary patients out of high-stress environments." This underscores the pressing need for innovation in medical diagnostics to enhance the efficiency and effectiveness of healthcare delivery.
About Ad Astra Diagnostics
Ad Astra Diagnostics, Inc. (AAD) is committed to providing rapid point-of-care diagnostics that enable swift healthcare decisions. Their QScout system is specifically designed to enhance health outcomes and optimize laboratory efficiency, embodying AAD's vision to democratize access to diagnostics and paying homage to its astronomical roots with the company name translating to "to the stars" in Latin. To learn more about their offerings, visit QScoutCBC.com.
Understanding Sepsis and CBC
About Sepsis
Sepsis represents an extreme response of the body to infection and is recognized as a medical emergency. It occurs when an infection triggers a systemic response that can lead to severe health complications or even death.
About the Complete Blood Count (CBC)
The complete blood count (CBC) is one of the most commonly ordered diagnostic tests, serving as a first line of triage. It offers screenings for multiple health conditions, such as infections, anemia, cancers, and internal bleeding.
In conclusion, the QScout™ and associated concepts—Information That Counts™ are trademarks belonging to Ad Astra Diagnostics, Inc.
Frequently Asked Questions
What is the significance of the BARDA contract awarded to AAD?
The BARDA contract enables AAD to develop an innovative diagnostic system aimed at delivering faster CBC test results and earlier infection detection, significantly impacting healthcare delivery.
How does the QScout CBC system work?
Users place a blood sample onto a test cartridge, which is then inserted into the QScout Lab. The system utilizes artificial intelligence to analyze the sample and return results in about two minutes.
What health conditions can a CBC test identify?
A CBC test screens for a range of health conditions, including infections, anemia, cancer, and internal bleeding, making it a critical tool in medical diagnostics.
Who is leading the development of the QScout CBC system?
Joy Parr Drach is the CEO of Ad Astra Diagnostics, leading the charge towards revolutionizing rapid diagnostics with the QScout CBC system.
What are the future implications of AAD's diagnostic technology?
By enhancing early detection capabilities for severe infections, AAD's technology aims to improve patient outcomes and efficacy in emergency healthcare settings.
